JAK3 A573V and JAK3 M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway.

J Immunother Cancer · 2025 · PMC11979606 · PMID 40199606

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

marginal significancep=0.055so close (0.05 < p ≤ 0.1)

PD-L1 exhibited marginal significance among distinct subtypes (Kruskal-Wallis, p=0.055; figure 1A ) and was still a predictor for PFS (HR: 0.99, 95% CI: 0.98 to 1.00, p=0.005) when adjusting for PTCL subtypes in the multivariate Cox regression algorithm ( figure 1C and online supplemental figure S1B ), indicating the strong and relatively independent predictive capability of PD-L1.

also in 2,590 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

&lt;i&gt;JAK3&lt;/i&gt; &lt;sup&gt;A573V&lt;/sup&gt; and &lt;i&gt;JAK3&lt;/i&gt; &lt;sup&gt;M511I&lt;/sup&gt; mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway.

The sentences

<i>JAK3</i> <sup>A573V</sup> and <i>JAK3</i> <sup>M511I</sup> mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway.